Neem’s Hill surpasses 5,000 Animal Care treatments sold as recurring kit sales grow

Growing treatment kit sales and usage of more than 150 treatments per year among advanced users indicate room for further growth through new installations and increased use within existing clinics.

Neem’s Hill AB announces that its Animal Care business has surpassed 5,000 treatments sold globally. This reflects the continued adoption of vetIQure™ Tumour Specific Electroporation (TSE) for veterinary cancer care in small companion animals and horses, and the contribution of recurring treatment kit sales to the business.

The vetIQure business model extends beyond the initial sale of a device to a veterinary clinic. Each treatment requires for safety and quality standards, a single-use treatment kit, generating recurring revenue as clinics integrate the technology into their oncology services.

Growth therefore comes from two complementary sources: placing additional devices in veterinary practices and increasing treatment activity within the existing customer base. As more clinics adopt vetIQure and established users gain experience across suitable indications, treatment kit demand can grow alongside the installed base.

Advanced users are already performing more than 150 treatments annually per clinic. This gives an indication of what may be achievable with clinical experience, appropriate patient selection and integration into everyday practice. It also provides a useful reference for supporting other clinics, while recognising that individual volumes will vary.

Clinical value for veterinary practices

For veterinarians, vetIQure offers an additional tool for treating cancer across a range of indications in small companion animals and horses. It can also help clinics expand their oncology services and offer more treatments within their practice.

Our vision is to bring the same commitment to quality and care to animals as we do to humans. In line with this vision, every vetIQure treatment uses a new, sterile, single-use treatment kit with clean, sharp electrodes, designed to support consistent performance each time a veterinarian treats an animal.

For suitable cases, incorporating vetIQure into the treatment pathway may help reduce the cost of care compared with some alternatives, while allowing clinics to offer an additional treatment service. The clinical and financial value will depend on the individual case and the needs of each practice.

To help customers develop their experience, an experienced vetIQure user hosted an invitation-only webinar for fellow users on November 2, 2026. The session focused on sharing practical experience and approaches to using the technology across different clinical situations and indications. Such exchanges can help users build confidence and identify suitable cases within their own practices.

Building on the installed base

“Surpassing 5,000 Animal Care treatments sold is an encouraging step for us,” said Mohan S Frick, CEO of Neem’s Hill AB. “Our advanced users are already performing more than 150 treatments per year, which gives us a useful indication of the potential within the installed base, which surpassing our own first estimates. We see room to grow both by reaching new clinics and by helping existing users build their treatment activity. Our focus is on supporting that development through clinical experience and close contact with our customers. We believe this can contribute to more consistent recurring revenue over time, while helping clinics offer valuable cancer care to more animals.”

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@neemshill.com

Neem's Hill AB (publ)

We are dedicated to manage, develop and market cost-effective, innovative solutions for tumor treatment in both humans and animals. Our goal is to create less destructive therapies that improve quality of life and extend life expectancy for the global population.

Neem's Hill's shares (NEEMS B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye Nordic Growth AB is the company's Certified Adviser. Read more at: www.neemshill.com.